Editorial comment from Dr Yuasa to Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma.
作者信息
Yuasa Takeshi
机构信息
Department of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Ariake Tokyo Japan.
出版信息
IJU Case Rep. 2020 Oct 7;3(6):291. doi: 10.1002/iju5.12228. eCollection 2020 Nov.
Abstract
摘要
相似文献
1
Editorial comment from Dr Yuasa to Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma.
IJU Case Rep. 2020 Oct 7;3(6):291. doi: 10.1002/iju5.12228. eCollection 2020 Nov.
2
Editorial Comment from Dr Kobayashi to Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma.
IJU Case Rep. 2020 Oct 5;3(6):292. doi: 10.1002/iju5.12225. eCollection 2020 Nov.
3
Editorial Comment from Dr Yuasa to Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma.
IJU Case Rep. 2020 Jul 27;3(5):218. doi: 10.1002/iju5.12199. eCollection 2020 Sep.
4
Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma.
IJU Case Rep. 2020 Oct 5;3(6):287-290. doi: 10.1002/iju5.12220. eCollection 2020 Nov.
5
Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.
Front Oncol. 2019 Oct 9;9:1033. doi: 10.3389/fonc.2019.01033. eCollection 2019.
6
Editorial Comment from Dr Yuasa to Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.
Int J Urol. 2018 Jun;25(6):604-605. doi: 10.1111/iju.13699. Epub 2018 May 15.
7
A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.
Medicina (Kaunas). 2022 Feb 23;58(3):336. doi: 10.3390/medicina58030336.
8
Editorial comment from Dr Yuasa to efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma.
Int J Urol. 2014 Oct;21(10):1069-70. doi: 10.1111/iju.12536. Epub 2014 Jun 26.
9
Editorial Comment from Dr Yuasa to Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.
Int J Urol. 2022 Jul;29(7):740. doi: 10.1111/iju.14920. Epub 2022 May 10.
10
Editorial Comment from Dr Kojima to Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma.
IJU Case Rep. 2020 Jul 24;3(5):219. doi: 10.1002/iju5.12203. eCollection 2020 Sep.
本文引用的文献
1
Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma.
IJU Case Rep. 2020 Oct 5;3(6):287-290. doi: 10.1002/iju5.12220. eCollection 2020 Nov.
2
Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience.
Urol Oncol. 2020 Oct;38(10):799.e1-799.e10. doi: 10.1016/j.urolonc.2020.07.021. Epub 2020 Aug 7.
3
Nivolumab treatment beyond progression for metastatic renal cell carcinoma: New role of metastasectomy in the immune checkpoint inhibitor era?
Int J Urol. 2020 Aug;27(8):691-692. doi: 10.1111/iju.14269. Epub 2020 May 31.
4
Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma.
Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-10. doi: 10.1200/EDBK_279881.
5
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
Ann Oncol. 2019 May 1;30(5):706-720. doi: 10.1093/annonc/mdz056.
Zotero 插件